ABEO — Abeona Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $206.53m
- $154.30m
- $3.50m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 10 | 3 | 1.41 | 3.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 77.1 | 91.4 | 91.1 | 52.3 | 50.6 |
Operating Profit | -77.1 | -81.4 | -88.1 | -50.9 | -47.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -76.3 | -84.2 | -84.9 | -39.7 | -54.2 |
Net Income After Taxes | -76.3 | -84.2 | -84.9 | -39.7 | -54.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -76.3 | -84.2 | -84.9 | -39.7 | -54.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -76.3 | -84.2 | -84.9 | -43.5 | -54.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -37.9 | -13.8 | -15.5 | -4.81 | -2.58 |